<DOC>
	<DOCNO>NCT00397046</DOCNO>
	<brief_summary>The purpose study assess tolerability safety HKI-272 , determine maximum dose safety give . The secondary purpose study determine body use get rid HKI-272 ass whether HKI-272 effective treatment advance solid tumor .</brief_summary>
	<brief_title>A Study Of The Safety And Tolerability Of HKI-272 Administered Orally To Japanese Subjects With Advanced Solid Tumors</brief_title>
	<detailed_description>This phase 1 open-label sequential-group study ascend single multiple oral dos administer subject advance solid tumor . Each subject participate 1 dose group receive single dose test article , follow 1-week observation period , receive test article administer once-daily mouth cycle consist 28 day . Subjects enrol group 3 6 . Adverse event dose-limiting toxicity assess first single dose .</detailed_description>
	<criteria>Inclusion criterion 1 . Diagnosis metastatic advance cancer fail standard effective therapy 2 . Life expectancy least 12 week adequate performance status 3 . Adequate bone marrow , kidney liver function 4 . Willingness male female subject surgically sterile postmenopausal use adequate method birth control Exclusion Criteria 1 . Any anticancer chemotherapy , radiotherapy immunotherapy investigational agent within 4 week first dose HKI272 2 . Inadequate cardiac function 3 . Surgery within 2 week first dose HKI272 4 . Active central nervous system metastasis ( i.e. , symptomatic , require use corticosteroid and/or progressive growth ) 5 . Significant gastrointestinal disorder diarrhea major symptom 6 . Pregnant breast feeding woman</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Advanced Malignant Solid Tumors</keyword>
</DOC>